Le requérant doit, à l’intention de l’IPI, dans un délai de 30 mois à compter de la date de dépôt ou de priorité:
250 Introduit par le ch. I de la LF du 17 déc. 1976 (RO 1977 1997; FF 1976 II 1). Nouvelle teneur selon le ch. I de la LF du 22 juin 2007, en vigueur depuis le 1er juil. 2008 (RO 2008 2551; FF 2006 1).
1 The Institute shall on application grant a supplementary protection certificate (certificate) for the active ingredients or combination of active ingredients of medicinal products. A certificate will only be issued if no paediatric supplementary protection certificate in accordance with Article 140t paragraph 1 is available.256
1bis An active ingredient is a substance of chemical or biological origin contributing to the composition of a medicinal product which has a medicinal effect on the organism. An active ingredient composition is a combination of several substances, all of which have a medicinal effect on the organism.257
2 Active ingredients or combinations of active ingredients are referred to in this Section as products.
255 Amended by No I of the FA of 9 Oct. 1998, in force since 1 May 1999 (AS 1999 1363; BBl 1998 1633).
256 Second sentence inserted by Annex No 2 of the FA of 18 March 2016, in force since 1 Jan. 2019 (AS 2017 2745, 2018 3575; BBl 2013 1).
257 Inserted by Annex No 2 of the FA of 18 March 2016, in force since 1 Jan. 2019 (AS 2017 2745, 2018 3575; BBl 2013 1).
Ceci n’est pas une publication officielle. Seule la publication opérée par la Chancellerie fédérale fait foi. Ordonnance sur les publications officielles, OPubl.
This document is not an official publication. Only the publication of the Federal Chancellery is legally binding.